Comparative Pharmacology
Head-to-head clinical analysis: AMINOCAPROIC ACID versus CYKLOKAPRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOCAPROIC ACID versus CYKLOKAPRON.
AMINOCAPROIC ACID vs CYKLOKAPRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by binding to plasminogen and blocking its conversion to plasmin.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by blocking the binding of plasminogen to fibrin.
Loading dose: 4-5 g intravenously (IV) over 1 hour, followed by continuous IV infusion of 1 g/hour for 8 hours or until bleeding controlled. Oral: 1 g every hour for 8 hours, then 1 g every 2 hours for 8 additional hours.
1 g (10 mL) IV over 5-10 minutes every 6-8 hours; or 25-50 mg/kg/day IV divided every 6-8 hours. Oral: 1-1.5 g 3-4 times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1-3 hours) in patients with normal renal function. Prolonged in renal impairment (up to 20 hours in anuria).
Clinical Note
moderateAminocaproic acid + Tretinoin
"Aminocaproic acid may increase the thrombogenic activities of Tretinoin."
Terminal elimination half-life: 2-3 hours (renal impairment extends to 10-20 hours).
Primarily renal (80-90% unchanged). A small fraction (<5%) is excreted as metabolites. No significant biliary/fecal elimination.
Renal: >95% as unchanged drug via glomerular filtration; minimal biliary/fecal (<5%).
Category C
Category C
Antifibrinolytic
Antifibrinolytic